April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
CMV-Retinitis: A Review of Treatment Procedures Between 1996 and 2009
Author Affiliations & Notes
  • C. H. Metz
    Department of Ophthalmology, University Hospital Essen, Essen, Germany
  • Footnotes
    Commercial Relationships  C.H. Metz, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5885. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. H. Metz; CMV-Retinitis: A Review of Treatment Procedures Between 1996 and 2009. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5885.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : We compared different treatments of CMV-retinitis in immunocompromised, immunocompetent and human immunodeficiency virus infected individuals.

Methods: : In a non-randomised, retrospective, interventional, non-comparative case series patients diagnosed with CMV-retinitis, either clinically or by biopsy, were reviewed. Between 1996 and 2009 a cohort of 7 patients/9 eyes received intravitreal ganciclovir injections (3mg/0.1ml) and 8 patients/ 10 eyes received a ganciclovir implant. In some cases diagnostic vitreous biopsy for polymerase chain reaction against CMV, VZV and HSV was performed. In most cases an intraveneous/oral therapy with either ganciclovir or forscanet was given additionally.

Results: : Follow-up time ranged between 3 months and 124 months (mean 20.47 months). An average number of 6.6 injections of ganciclovir (between 2 and 28) were necessary to treat the CMV-retinitis. The mean visual acuity dropped by 8 lines from logmar 0.54 to logmar 1.3056 at final visit. In the injection group four of nine eyes showed retinal detachment in the course of the disease and was treated by vitrectomy and two eyes developed amaurosis.None of ten eyes of the ganciclovir implant group showed retinal detachment, but one of ten eyes needed to be treated due to vitreous bleeding, one of ten eyes had to be enucleated and one out of ten eyes were operated due to macular pucker. Two out of ten eyes developed an amaurosis. In the group of patients treated with ganciclovir implants only one patient needed more than one implant. Mean visual acuity dropped by 8 lines from logmar 0,34 to logmar 1,1 at final visit.

Conclusions: : CMV-retinitis is a devastating disease for the eye. Just in two cases, one in the implant group and one in the injection group, visual acuity could be improved. No treatment procedure showed more favourable results than the other. The main complication in this disease is a retinal detachment. We advise prompt diagnoses and treatment of the disease and frequent controls even after inflammation has stopped.

Keywords: cytomegalovirus • retinitis • inflammation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.